Top 10 Daridorexant (Quviviq) Generic Manufacturers in India
The pharmaceutical industry in India has witnessed substantial growth, driven by the increasing demand for affordable medications and the expansion of healthcare infrastructure. As of 2023, the Indian pharmaceutical market is valued at approximately $42 billion and is projected to reach $65 billion by 2024. With a growing focus on generics, the market share of generic drugs is estimated to be around 70% in terms of volume, reflecting the country’s position as a global hub for affordable pharmaceuticals. This report outlines the top 10 manufacturers of Daridorexant (Quviviq) generics in India, highlighting their production capabilities and market relevance.
1. Sun Pharmaceutical Industries Ltd.
Sun Pharma is one of India’s largest pharmaceutical companies, with a market share of approximately 8.5%. The company has a robust production capacity, manufacturing over 1,000 generic formulations across various therapeutic segments. Their generics portfolio includes Daridorexant, contributing significantly to their annual revenue of around $4.5 billion.
2. Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s ranks among the top pharmaceutical companies in India, holding a market share of about 4.5%. The company has a well-established manufacturing unit that produces a variety of generics, including Daridorexant, with an annual production capacity of over 200 million units. Their revenue for 2022 was approximately $2.1 billion.
3. Cipla Ltd.
Cipla is a major player in the Indian pharmaceutical sector, boasting a market share of around 6%. With a focus on high-quality generics, Cipla produces Daridorexant, leveraging its advanced manufacturing facilities. The company’s annual revenue exceeds $2.8 billion, reflecting its strong market presence.
4. Lupin Pharmaceuticals
Lupin Pharmaceuticals holds a market share of 5% and is known for its extensive range of generic drugs. The company manufactures Daridorexant in its state-of-the-art facilities, contributing to an annual revenue of approximately $2.3 billion. Lupin’s commitment to quality and compliance enhances its competitive edge.
5. Aurobindo Pharma Ltd.
Aurobindo Pharma is recognized for its diverse generic portfolio, with a market share of about 4%. The company produces Daridorexant and has an impressive manufacturing output, with over 200 million units produced annually. Their revenue for 2022 was around $2 billion, showcasing their growth trajectory.
6. Zydus Cadila
Zydus Cadila is a prominent player in the Indian pharmaceutical market, with a market share of approximately 3.5%. The company produces a wide range of generics, including Daridorexant, through its advanced manufacturing facilities. Their annual revenue stands at about $1.5 billion.
7. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals has a market share of around 3% and is known for its innovative approach in generics. The company manufactures Daridorexant and has a production capacity of over 150 million units annually. Their revenue for 2022 was approximately $1.6 billion.
8. Torrent Pharmaceuticals
Torrent Pharmaceuticals holds a market share of about 2.5%. The company has a robust generic manufacturing line, producing Daridorexant among other therapeutics. Torrent’s annual revenue is approximately $1.4 billion, reflective of its strong performance in the market.
9. Alkem Laboratories Ltd.
Alkem Laboratories has a market share of around 2%. The company specializes in high-quality generics and produces Daridorexant with a production capacity of over 100 million units. Their revenue for 2022 was approximately $1.2 billion, indicating solid growth.
10. Mylan N.V. (now part of Viatris)
Mylan, now part of Viatris, has a market share of about 1.5%. The company is recognized for its extensive portfolio of generic drugs, including Daridorexant, with a production capacity that supports high-volume demand. Their revenue is estimated at $1 billion, underscoring their significance in the generics market.
Insights
The generics market in India is poised for continued growth, driven by increasing healthcare needs and rising investments in pharmaceutical infrastructure. The Indian government’s initiatives to boost local manufacturing capabilities and reduce dependency on imports are likely to enhance the production of generics like Daridorexant. In 2023, the generic drugs segment is expected to account for over 70% of the total pharmaceutical market volume, reflecting a growing trend toward cost-effective healthcare solutions. As the global demand for affordable medications rises, India’s pharmaceutical companies are likely to expand their production capacities, enhancing their competitive positions both domestically and internationally.
Related Analysis: View Previous Industry Report
